US3875300A - Composition for sustained release of a medicament and method of using same - Google Patents
Composition for sustained release of a medicament and method of using same Download PDFInfo
- Publication number
- US3875300A US3875300A US316175A US31617572A US3875300A US 3875300 A US3875300 A US 3875300A US 316175 A US316175 A US 316175A US 31617572 A US31617572 A US 31617572A US 3875300 A US3875300 A US 3875300A
- Authority
- US
- United States
- Prior art keywords
- composition
- spermicide
- medicament
- ethanol
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
Definitions
- ABSTRACT A solid, intimately admixed compostion comprising a thermoplastic, physiologically-inert polymer soluble in body fluids, andan effective amount of a suitable medicament.
- the composition is suitable for introduction into a body cavity, therein to be slowly dissolved by body fluids and release thereby incremental amounts of medicament.
- Various areas of use include intravaginal applications for spermicidal effect, subcutaneous implantation, and the, like.
- the present invention relates to an improved medicament dispensing system of special use in contraception. More particularly it relates to a composition of matter useful for delivering controlled amounts of a medicament within a body cavity at a pre-determined rate.
- Delivery of medicaments to a site within a body cavity is usually accomplished either systemically by oral administration or locally by direct introduction into the cavity.
- the systemic method has the advantage of being convenient, but because it is systemic suffers from side effect" problems.
- Direct introduction has the advantage of requiring lower doses and is faster acting, but is also usually very inconvenient and quite often unpredictable in efficacy.
- the concentration of medicament in the body cavity is not maintained at a constant level, but is rather at a maximum just after application and declines thereafter.
- it is necessary when using the direct introduction method to give either a moderate excess at short intervals or a large excess at longer intervals. Neither of these alternatives is satisfactorily convenient or economical.
- contraception One of the areas of major interest as regards direct introduction of medicaments into body cavities is contraception.
- Several contraceptive methods are currently employed. For example, there are those which prevent ovulation, those which prevent implantation, and those which prevent sperm from coming in contact with a released ovum.
- the first method is typified by oral administration of various drugs, usually steroids, and has the disadvantage of being systemic rather than topical. It is advantageous, however, in that administration immediately prior to coitus is not necessary.
- the second method is typified by insertion into the uterus and maintenance therein of a foreign object called an intrauterine device.
- This method has the advantage of the first method and is also topical, but is disadvantageous because of the undesirably high possibility of perforating the uterus.
- the devices are usually painful during the insertion process and usually for long periods thereafter during residency.
- a third method usually involves placing some physical or chemical barrier between the sperm and the ovum and is typified by a condom, a spermicidal foam or jelly, and the like, or a combination of two or more of these.
- This third type has the disadvantage of requiring application just prior to coitus, but has the advantages of being topical in application and having no extravaginal effects.
- This method would be very desirable indeed if application of the material were required not immediately before coitus but rather at some prior time much in advance of coitus.
- the present invention provides a system and method especially suited for contraceptive use of the third type, but capable of broader applications which does not have the disadvantages traditionally associated with it. That is, the invention provides a solid drug delivery system of the type which is inserted into the vagina up to 24 hours prior to coitus and slowly releases a spermicide. The system does not require removal or storage after use since it is soluble in body fluids and is diffused by the system.
- the present invention therefore, in its broader aspects provides a solid drug delivery system comprising in intimate admixture a body fluid-soluble, thermoplastic, physiologically-inert polymer and an effective amount ofa suitable medicament.
- medicament includes but is not limited to spermicides, ovacides, antimicrobials, anti-inflammatories, steroidal and non-steroidal anti-fertility agents, prostaglandins, and the like, and includes any compound, drug or medicine having a desired physiological effect.
- the polymer may be any of those which are soluble in body fluids such as, for example, a cellulose, a starch, an alginate, a polyvinyl alcohol, a polyvinyl pyrrolidone, a polyacrylamide, an ethyleneoxide polymer, or the like.
- the solubility characteristics of the polymer are chosen so that the entire mass is totally dissolved in the body cavity fluids within a period of about 24 hours so as to give a sustained, prolonged release of medicament.
- the preferred polymer is a hydroxypropyl cellulose or hydroxypropylmethyl cellulose having a molecular weight of from 60,000 to 1,000,000.
- cellulose ethers having a high degree of ideal propyl substitution at the hydroxyl groups. From to I00 percent propyl substitution is suitable.
- the product of the invention may be provided in the form of fibers, molded articles or extruded shapes, in which form they may then be placed in the body cavity where they will dissolve and release the medicament at a desirable rate.
- composition of the present invention will contain various amounts of polymer and medicament relative to one another depending upon many factors including the final use to which the composition will be put, the nature of the drug employed, the actual solubility characteristics of the polymer, and the like. In general, however, a composition containing up to about 30 weight percent of the medicament with the balance being essentially polymer will be suitable. Preferably, however, the amount of medicament ranges from 5 to 25 percent by weight based on the weight of the entire composition. Such a formulation is especially suitable for contraceptive use when the composition comprises a spermicide as the medicament and hydroxypropyl cellulose as the polymer.
- compositions of the present invention are prepared by intimately blending the desired polymer in any convenient form such as pellet or powder form with the appropriate amount of medicament. This intimate mixture is then spun, cast, molded, or extruded into fibers or suitable shapes, either with or without the addition of solvents or additional plasticizers.
- hydroxypropyl cellulose As illustrative, a typical preparation is as follows: Hydroxypropyl cellulose powder is intimately mixed with a suitable amount of a medicament, preferably a spermicide. The resulting mixture is melt spun using standard spinning techniques into a strand and the strand chopped into pellets. These pellets are then charged into a standard melt spinning apparatus, are spun into fine fibers and the fibers chopped into lengths convenient for subsequently forming cotton' balls from the fibers. Dry carding techniques are then employed to form cotton balls or wads. There results from this operation the preferred form of the composition of the invention when an intravaginal contraceptive system is sought.
- the pellets may, on the other hand, be used in the molding or extrusion of a suitable shape, e.g., a circular film, a diaphragm, or the like.
- the techniques of fiber formation may vary depending on the particular polymer being used, but these techniques are all within the skill of the art and basically form no part of the present invention.
- a suitable coagulating agent e.g.,'Na SO,, (NH SO MgSO or the like
- Standard wet spinning techniques are also employed when using hydroxypropylmethyl cellulose.
- the preferred composition of the present invention is a mixture of hydroxypropyl cellulose with a spermicide, preferably in the form of a fibrous mass.
- the spermicide may be any compound known to be spermicidal and compatible with the polymeric system used. Typically acceptable are non-ionic surfactants such as ethoxylated phenoxyethanols.
- Such materials are well known in the art and are represented by pdiisobutylphenoxypolyethoxy ethanol, known as Triton X-l00, available from Rohm & Haas, Philadelphia, Pa., nonylphenoxypoly(ethoxy),, ethanol (where n is an integer up to 21 and preferably 9), known as Tergitol TP-9 available from Union Carbide, New York, N.Y., also known as Nonoxynol, available from General Aniline & Film Corp., New York, NY.
- Other spermicides include ricinoleic acid and mercurial salts such as phenyl mercuric acetate.
- the preferred spermicides are the nonylphenoxypoly(ethoxy),, ethanols with that compound wherein n is 9 being most preferred.
- the fibrous mass suitably comprises polymerspermicide fibers having a strand diameter of up to 50 denier (about 5.5 mils.) and preferably from 0.0004 to 0.0015 inches, and a strand length of from 0.25 to 2 inches and preferably 0.5 to 1.25 inches.
- the mass has a bulk density of 0.1 to 0.3 and preferably 0.1 l to 0.15 gms. per cc in the relaxed state.
- Such dimensions give a product having the appearance of cotton wadding but having sufficient resiliency and elasticity for filling the cross-section of the vaginal canal and providing occlusion of the deep inner recesses and folds, which might otherwise not receive spermicide were a foam, jelly or cream used.
- an effective fibrous mass weighs between 0.75 and 1.50 gms. and preferably 1.00 to 1.25 gms. It may be inserted into the vaginal canal using any of the well-known insertion techniques up to 16-24 hours before coitus. A mass of the weight and dimensions described will slowly dissolve over this period in the natural body fluids and will supply an effective dose of spermicide. It thus provides both a physical and chemical barrier to the union of sperm and ovum in a safe, reliable, topical and aesthetic fashion.
- Observations of residence times of various embodiments of the present invention in several types of experimental animals indicate that it has the desired residence time (about 16 hours) in any warm-blooded animal if used at an appropriate dose.
- fibrous masses weighing 1.00 to 1.25 gms. will have 0.10 to 0.125 gms. of spermicide associated therewith, and this will ordinarily be suitable for virtually complete spermicidal activity over a 16- hour period.
- Other compositions of the invention, whether fibrous or molded or extruded shapes behave similarly and are easily adaptable to insertion into any body cavity therein to release drug.
- EXAMPLE 1 lnto an oscillating drum mixer are charged 15,2000 gms. of powdered food grade hydroxypropyl cellulose (available under the tradename Klucel G (available from Hercules, lnc., Wilmington, Del., having a molecular weight of 275,000 and an idealized molar substitution of 3.0 and 1,800 gms. of diisobutylphenoxypolyethoxy ethanol, available under the name of Triton X- 100, from Rohm & Haas, Philadelphia, Pa.
- the blend is intimately mixed and the resulting intimate mixture is charged into a 2-inch Davis-type single screw extruder equipped with a die containing six /s-inch circular orifices.
- the Extruder has three zones of melting electrically maintained at 325F, 315F, and 330F, respectively.
- the strands are cooled as they travel down a 30-foot teflon-coated trough, at the end of which is a means for chopping the strands into /2 inch lengths.
- the resulting pellets are graded for size, the scraps being returned to the extruder for reuse.
- the pellets are then re-extruded as above on a l-inch Davis-type extruder equipped with a die containing a 0.018 inch circular orifice and a means for attenuating the strand as it emerges. This monofilament is collected and is chopped into lengths of between about /2 inch and about 2 inches. These lengths are then treated by standard dry-carding techniques to yield fibrous masses of the cotton wad type.
- Example II The procedure of Example I is repeated except that 15 percent by weight of the spermicide is substituted for the 10 percent used therein.
- Example 1 The procedure of Example 1 is repeated except that 25 percent by weight of the spermicide is substituted for the 10 percent used therein.
- Example V The procedure of Example IV is repeated except that 15 percent by weight of spermicide is substituted for the 10 percent used therein.
- EXAMPLE VI A wad of fibers as produced in Example 11 and weighing 0.300 gms. is inserted into the vagina of a female rhesus monkey and is observed periodically. Dissolution of the polymer begins immediately and continues until the wad disappears, a period of from about 17 to about 24 hours.
- EXAMPLE Vll Into a tank are charged parts by weight of a watersoluble copolymer of polyvinyl alcohol and allyl alcohol prepared in accordance with known techniques, (See Example I of US. Pat. No. 2,909,502), 5 parts by weight of the spermicide Triton X-l (diisobutylphenoxypolyethoxy ethanol) and sufficient water to make a l percent by weight spinning solution of the spermicide mixture. After thorough mixing, filtration, and de-aeration of the spinning solution, fiber is spun from the solution by the wet method, the coagulating solution for which is a 50C aqueous solution containing about 420g/liter of Na SO and having a pH of about 3.9. The monofilament is collected and chopped into staples (-l inch lengths) suitable for formation into cotton balls by standard dry carding techniques.
- Triton X-l diisobutylphenoxypolyethoxy ethanol
- Example VIII The procedure of Example VII is repeated except that 15 percent by weight of spermicide is substituted for the 5 percent used therein.
- Example VII The procedure of Example VII is repeated except that 25 percent by weight of spermicide is substituted for the 5 percent used therein.
- Example VII The procedure of Example VII is repeated except that 5 percent by weight of Tergitol TP-9 is substituted for the spermicide used therein.
- Example XI The procedure of Example X is repeated except that 10 percent by weight of spermicide is substituted for the 5 percent used therein.
- Example XII The procedure of Example X is repeated except that percent by weight of spermicide is substituted for the 5 percent used therein.
- Example XIII The procedure of Example VII is repeated except that an equal weight ofeach of ricinoleic acid, and phenyl mercuric acetate is substituted for the 5 percent by weight of Triton X-l00 used therein.
- EXAMPLE XIV Several fibers as produced in Example II are dissolved in saline solution and are added to rabbit semen samples in vitro. Immobilization of the sperm is observed to occur. Similar results are obtained when the fibers of Examples l-XIV are utilized in this manner.
- a composition of matter comprising an intimate admixture of a thermoplastic, physiologically-inert hydroxypropyl cellulose or hydroxypropylmethyl cellulose polymer soluble in vaginal fluids shaped as an intra-vaginal medicament applicator and up to 30 weight percent of a vaginal medicament, said intimate mixture having been melt spun by being melted, spun, cast, molded or extruded in the molten state into a fibrous mass of fine fibers, strands, pellets, balls or wads, the entire mass totally dissolving in said vaginal fluid within about 24 hours.
- composition of claim 1 wherein the polymer is hydroxypropyl cellulose.
- composition of claim 2 in which the medicament is a spermicide, ovacide, antimicrobial, prostaglandin, steroidal or non-steroidal antifertility agent.
- composition of claim 3 wherein the medicament is a spermicide.
- composition of claim 4 wherein the spermicide is present in an amount ranging from 5 to 25 percent by weight based on the weight of the entire composition.
- composition of claim wherein the polymer is a hydroxypropyl cellulose.
- composition of claim 6 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol wherein n is 9.
- composition of claim 6 wherein the spermicide is p-diisobutylphenoxypolyethoxy ethanol.
- composition of claim 5 wherein the polymer is a hydroxypropylmethyl cellulose.
- composition of claim 9 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol or pdiisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.
- composition ofclaim 6 wherein the composition is in the form of a fibrous mass having a fiber diameter of from 0.0004 to 0.0015 inches, and a bulk density of from 0.1 l to 0.15 gms. per cubic cm.
- composition of claim 11 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol or pdiisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.
- the method for delivering a vaginal medicament to a site within the vagina from a solid medicament delivery system which comprises introducing within the vagina an effective amount of the composition of claim 1.
- composition employed is from 5 to 25 percent by weight of a spermicide admixed in a hydroxypropyl cellulose.
- COMPOSITIN should read COMPOSITION In Column 1, line 1, in Title, "COMPOSI'IIN” should read COWOSITION Q In Column 2, line 7, "anti-fertility” should read antifertility In (301 2 line 63, The word cotton should be in quotation marks.
Abstract
A solid, intimately admixed composition comprising a thermoplastic, physiologically-inert polymer soluble in body fluids, and an effective amount of a suitable medicament. The composition is suitable for introduction into a body cavity, therein to be slowly dissolved by body fluids and release thereby incremental amounts of medicament. Various areas of use include intravaginal applications for spermicidal effect, subcutaneous implantation, and the like.
Description
Homm et al.
Apr. 1, 1975 COMPOSITIN FOR SUSTAINED RELEASE OF A MEDICAMENT AND METHOD OF USING SAME Inventors: Roger Homm, Neshanic; Gilbert Katz, Boonton, both of NJ.
Ortho Pharmaceutical Corporation, Rariton, NJ.
Filed: Dec. 18, 1972 Appl. No.: 316,175
Assignee:
us. c1 ..424/28, 424/27, 128/260, 128/270, 128/271, 128/285 1111. c1 A611 19/00 Field 01 Search 424/27, 28; 128/260, 270, 128/271, 285
References Cited UNlTED STATES PATENTS 12/1962 Morton ct a1 1. 424/28 3,108,043 10/1963 Millman et a1 424/27 X FOREIGN PATENTS OR APPLICATIONS 263,153 3/1960 Australia 722,629 l/1955 United Kingdom 735,370 8/1955 United Kingdom Primary E.\'aminerShep K. Rose Attorney, Agent, or Firm-Benjamin F. Lambert [57] ABSTRACT A solid, intimately admixed compostion comprising a thermoplastic, physiologically-inert polymer soluble in body fluids, andan effective amount of a suitable medicament. The composition is suitable for introduction into a body cavity, therein to be slowly dissolved by body fluids and release thereby incremental amounts of medicament. Various areas of use include intravaginal applications for spermicidal effect, subcutaneous implantation, and the, like.
14 Claims, N0 Drawings COMPOSITIN FOR SUSTAINED RELEASE OF A MEDICAMENT AND METHOD OF USING SAME BACKGROUND OF THE INVENTION The present invention relates to an improved medicament dispensing system of special use in contraception. More particularly it relates to a composition of matter useful for delivering controlled amounts of a medicament within a body cavity at a pre-determined rate.
Delivery of medicaments to a site within a body cavity is usually accomplished either systemically by oral administration or locally by direct introduction into the cavity. The systemic method has the advantage of being convenient, but because it is systemic suffers from side effect" problems. Direct introduction has the advantage of requiring lower doses and is faster acting, but is also usually very inconvenient and quite often unpredictable in efficacy. In this method, the concentration of medicament in the body cavity is not maintained at a constant level, but is rather at a maximum just after application and declines thereafter. Thus, in order to have an effective amount of medicament in the body cavity at all times, it is necessary when using the direct introduction method to give either a moderate excess at short intervals or a large excess at longer intervals. Neither of these alternatives is satisfactorily convenient or economical.
One of the areas of major interest as regards direct introduction of medicaments into body cavities is contraception. Several contraceptive methods are currently employed. For example, there are those which prevent ovulation, those which prevent implantation, and those which prevent sperm from coming in contact with a released ovum. The first method is typified by oral administration of various drugs, usually steroids, and has the disadvantage of being systemic rather than topical. It is advantageous, however, in that administration immediately prior to coitus is not necessary.
The second method is typified by insertion into the uterus and maintenance therein of a foreign object called an intrauterine device. This method has the advantage of the first method and is also topical, but is disadvantageous because of the undesirably high possibility of perforating the uterus. Moreover, the devices are usually painful during the insertion process and usually for long periods thereafter during residency.
A third method usually involves placing some physical or chemical barrier between the sperm and the ovum and is typified by a condom, a spermicidal foam or jelly, and the like, or a combination of two or more of these. This third type has the disadvantage of requiring application just prior to coitus, but has the advantages of being topical in application and having no extravaginal effects. This method would be very desirable indeed if application of the material were required not immediately before coitus but rather at some prior time much in advance of coitus.
The present invention provides a system and method especially suited for contraceptive use of the third type, but capable of broader applications which does not have the disadvantages traditionally associated with it. That is, the invention provides a solid drug delivery system of the type which is inserted into the vagina up to 24 hours prior to coitus and slowly releases a spermicide. The system does not require removal or storage after use since it is soluble in body fluids and is diffused by the system. The present invention, therefore, in its broader aspects provides a solid drug delivery system comprising in intimate admixture a body fluid-soluble, thermoplastic, physiologically-inert polymer and an effective amount ofa suitable medicament. The term medicament includes but is not limited to spermicides, ovacides, antimicrobials, anti-inflammatories, steroidal and non-steroidal anti-fertility agents, prostaglandins, and the like, and includes any compound, drug or medicine having a desired physiological effect.
The polymer may be any of those which are soluble in body fluids such as, for example, a cellulose, a starch, an alginate, a polyvinyl alcohol, a polyvinyl pyrrolidone, a polyacrylamide, an ethyleneoxide polymer, or the like. Preferably, the solubility characteristics of the polymer are chosen so that the entire mass is totally dissolved in the body cavity fluids within a period of about 24 hours so as to give a sustained, prolonged release of medicament. Where vaginal use is contemplated, the preferred polymer is a hydroxypropyl cellulose or hydroxypropylmethyl cellulose having a molecular weight of from 60,000 to 1,000,000. Typically employable here are cellulose ethers having a high degree of ideal propyl substitution at the hydroxyl groups. From to I00 percent propyl substitution is suitable. The product of the invention may be provided in the form of fibers, molded articles or extruded shapes, in which form they may then be placed in the body cavity where they will dissolve and release the medicament at a desirable rate.
The composition of the present invention will contain various amounts of polymer and medicament relative to one another depending upon many factors including the final use to which the composition will be put, the nature of the drug employed, the actual solubility characteristics of the polymer, and the like. In general, however, a composition containing up to about 30 weight percent of the medicament with the balance being essentially polymer will be suitable. Preferably, however, the amount of medicament ranges from 5 to 25 percent by weight based on the weight of the entire composition. Such a formulation is especially suitable for contraceptive use when the composition comprises a spermicide as the medicament and hydroxypropyl cellulose as the polymer.
The compositions of the present invention are prepared by intimately blending the desired polymer in any convenient form such as pellet or powder form with the appropriate amount of medicament. This intimate mixture is then spun, cast, molded, or extruded into fibers or suitable shapes, either with or without the addition of solvents or additional plasticizers.
For example, using hydroxypropyl cellulose as illustrative, a typical preparation is as follows: Hydroxypropyl cellulose powder is intimately mixed with a suitable amount of a medicament, preferably a spermicide. The resulting mixture is melt spun using standard spinning techniques into a strand and the strand chopped into pellets. These pellets are then charged into a standard melt spinning apparatus, are spun into fine fibers and the fibers chopped into lengths convenient for subsequently forming cotton' balls from the fibers. Dry carding techniques are then employed to form cotton balls or wads. There results from this operation the preferred form of the composition of the invention when an intravaginal contraceptive system is sought. The pellets may, on the other hand, be used in the molding or extrusion of a suitable shape, e.g., a circular film, a diaphragm, or the like.
The techniques of fiber formation may vary depending on the particular polymer being used, but these techniques are all within the skill of the art and basically form no part of the present invention. For example, when polyvinyl alcohol is used as the polymer, wet spinning techniques, using an aqueous solution of a suitable coagulating agent, e.g.,'Na SO,, (NH SO MgSO or the like may be employed. Standard wet spinning techniques are also employed when using hydroxypropylmethyl cellulose.
As stated, the preferred composition of the present invention is a mixture of hydroxypropyl cellulose with a spermicide, preferably in the form of a fibrous mass. The spermicide may be any compound known to be spermicidal and compatible with the polymeric system used. Typically acceptable are non-ionic surfactants such as ethoxylated phenoxyethanols. Such materials are well known in the art and are represented by pdiisobutylphenoxypolyethoxy ethanol, known as Triton X-l00, available from Rohm & Haas, Philadelphia, Pa., nonylphenoxypoly(ethoxy),, ethanol (where n is an integer up to 21 and preferably 9), known as Tergitol TP-9 available from Union Carbide, New York, N.Y., also known as Nonoxynol, available from General Aniline & Film Corp., New York, NY. Other spermicides include ricinoleic acid and mercurial salts such as phenyl mercuric acetate. Among the above, the preferred spermicides are the nonylphenoxypoly(ethoxy),, ethanols with that compound wherein n is 9 being most preferred.
The fibrous mass suitably comprises polymerspermicide fibers having a strand diameter of up to 50 denier (about 5.5 mils.) and preferably from 0.0004 to 0.0015 inches, and a strand length of from 0.25 to 2 inches and preferably 0.5 to 1.25 inches. Normally the mass has a bulk density of 0.1 to 0.3 and preferably 0.1 l to 0.15 gms. per cc in the relaxed state. Such dimensions give a product having the appearance of cotton wadding but having sufficient resiliency and elasticity for filling the cross-section of the vaginal canal and providing occlusion of the deep inner recesses and folds, which might otherwise not receive spermicide were a foam, jelly or cream used. Typically, an effective fibrous mass weighs between 0.75 and 1.50 gms. and preferably 1.00 to 1.25 gms. It may be inserted into the vaginal canal using any of the well-known insertion techniques up to 16-24 hours before coitus. A mass of the weight and dimensions described will slowly dissolve over this period in the natural body fluids and will supply an effective dose of spermicide. It thus provides both a physical and chemical barrier to the union of sperm and ovum in a safe, reliable, topical and aesthetic fashion.
Observations of residence times of various embodiments of the present invention in several types of experimental animals (tabulated in FIG. 1) indicate that it has the desired residence time (about 16 hours) in any warm-blooded animal if used at an appropriate dose. For example, fibrous masses weighing 1.00 to 1.25 gms. will have 0.10 to 0.125 gms. of spermicide associated therewith, and this will ordinarily be suitable for virtually complete spermicidal activity over a 16- hour period. Other compositions of the invention, whether fibrous or molded or extruded shapes, behave similarly and are easily adaptable to insertion into any body cavity therein to release drug.
The following examples are given to illustrate specific embodiments of the present invention:
EXAMPLE 1 lnto an oscillating drum mixer are charged 15,2000 gms. of powdered food grade hydroxypropyl cellulose (available under the tradename Klucel G (available from Hercules, lnc., Wilmington, Del., having a molecular weight of 275,000 and an idealized molar substitution of 3.0 and 1,800 gms. of diisobutylphenoxypolyethoxy ethanol, available under the name of Triton X- 100, from Rohm & Haas, Philadelphia, Pa. The blend is intimately mixed and the resulting intimate mixture is charged into a 2-inch Davis-type single screw extruder equipped with a die containing six /s-inch circular orifices. The Extruder has three zones of melting electrically maintained at 325F, 315F, and 330F, respectively. The strands are cooled as they travel down a 30-foot teflon-coated trough, at the end of which is a means for chopping the strands into /2 inch lengths. The resulting pellets are graded for size, the scraps being returned to the extruder for reuse.
The pellets are then re-extruded as above on a l-inch Davis-type extruder equipped with a die containing a 0.018 inch circular orifice and a means for attenuating the strand as it emerges. This monofilament is collected and is chopped into lengths of between about /2 inch and about 2 inches. These lengths are then treated by standard dry-carding techniques to yield fibrous masses of the cotton wad type.
EXAMPLE II The procedure of Example I is repeated except that 15 percent by weight of the spermicide is substituted for the 10 percent used therein.
EXAMPLE "I The procedure of Example 1 is repeated except that 25 percent by weight of the spermicide is substituted for the 10 percent used therein.
EXAMPLE [V The procedure of Example I is repeated except that 5 percent by weight of nonylphenoxypoly(ethoxy),, ethanol, n 9, (available from Union Carbide Corp., New York, N.Y., under the name of Tergitol TP-9) is substituted for the 10 percent by weight of Triton X-100 used therein.
EXAMPLE V The procedure of Example IV is repeated except that 15 percent by weight of spermicide is substituted for the 10 percent used therein.
EXAMPLE VI A wad of fibers as produced in Example 11 and weighing 0.300 gms. is inserted into the vagina of a female rhesus monkey and is observed periodically. Dissolution of the polymer begins immediately and continues until the wad disappears, a period of from about 17 to about 24 hours.
EXAMPLE Vll Into a tank are charged parts by weight of a watersoluble copolymer of polyvinyl alcohol and allyl alcohol prepared in accordance with known techniques, (See Example I of US. Pat. No. 2,909,502), 5 parts by weight of the spermicide Triton X-l (diisobutylphenoxypolyethoxy ethanol) and sufficient water to make a l percent by weight spinning solution of the spermicide mixture. After thorough mixing, filtration, and de-aeration of the spinning solution, fiber is spun from the solution by the wet method, the coagulating solution for which is a 50C aqueous solution containing about 420g/liter of Na SO and having a pH of about 3.9. The monofilament is collected and chopped into staples (-l inch lengths) suitable for formation into cotton balls by standard dry carding techniques.
EXAMPLE VIII The procedure of Example VII is repeated except that 15 percent by weight of spermicide is substituted for the 5 percent used therein.
EXAMPLE IX The procedure of Example VII is repeated except that 25 percent by weight of spermicide is substituted for the 5 percent used therein.
EXAM PLE X The procedure of Example VII is repeated except that 5 percent by weight of Tergitol TP-9 is substituted for the spermicide used therein.
EXAMPLE XI The procedure of Example X is repeated except that 10 percent by weight of spermicide is substituted for the 5 percent used therein.
EXAMPLE XII The procedure of Example X is repeated except that percent by weight of spermicide is substituted for the 5 percent used therein.
EXAMPLE XIII The procedure of Example VII is repeated except that an equal weight ofeach of ricinoleic acid, and phenyl mercuric acetate is substituted for the 5 percent by weight of Triton X-l00 used therein.
EXAMPLE XIV Several fibers as produced in Example II are dissolved in saline solution and are added to rabbit semen samples in vitro. Immobilization of the sperm is observed to occur. Similar results are obtained when the fibers of Examples l-XIV are utilized in this manner.
What is claimed is:
l. A composition of matter comprising an intimate admixture of a thermoplastic, physiologically-inert hydroxypropyl cellulose or hydroxypropylmethyl cellulose polymer soluble in vaginal fluids shaped as an intra-vaginal medicament applicator and up to 30 weight percent of a vaginal medicament, said intimate mixture having been melt spun by being melted, spun, cast, molded or extruded in the molten state into a fibrous mass of fine fibers, strands, pellets, balls or wads, the entire mass totally dissolving in said vaginal fluid within about 24 hours.
2. The composition of claim 1 wherein the polymer is hydroxypropyl cellulose.
3. The composition of claim 2 in which the medicament is a spermicide, ovacide, antimicrobial, prostaglandin, steroidal or non-steroidal antifertility agent.
4. The composition of claim 3 wherein the medicament is a spermicide.
5. The composition of claim 4 wherein the spermicide is present in an amount ranging from 5 to 25 percent by weight based on the weight of the entire composition.
6. The composition of claim wherein the polymer is a hydroxypropyl cellulose.
7. The composition of claim 6 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol wherein n is 9.
8. The composition of claim 6 wherein the spermicide is p-diisobutylphenoxypolyethoxy ethanol.
9. The composition of claim 5 wherein the polymer is a hydroxypropylmethyl cellulose.
10. The composition of claim 9 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol or pdiisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.
11. The composition ofclaim 6 wherein the composition is in the form of a fibrous mass having a fiber diameter of from 0.0004 to 0.0015 inches, and a bulk density of from 0.1 l to 0.15 gms. per cubic cm.
12. The composition of claim 11 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol or pdiisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.
13. The method for delivering a vaginal medicament to a site within the vagina from a solid medicament delivery system which comprises introducing within the vagina an effective amount of the composition of claim 1.
14. The method of claim 13 wherein the composition employed is from 5 to 25 percent by weight ofa spermicide admixed in a hydroxypropyl cellulose.
1 UNITED STATES PATENT OFFICE tmwmmm Patent No. 3, 75,3 Dated Ap l 975 Inventor(s) Roger Homm and Gilbert Katz It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
rm n w Page 1, in Title, COMPOSITIN should read COMPOSITION In Column 1, line 1, in Title, "COMPOSI'IIN" should read COWOSITION Q In Column 2, line 7, "anti-fertility" should read antifertility In (301 2 line 63, The word cotton should be in quotation marks.
In Column bline 10, "Wilmin ton, Del., having" should read Wilmington, Del.), having igntd an said this fifth Day of August 1975 [SEAL] Arrest.-
RUTH C. MASON C. MARSHALL DANN Allvsring ()jficer ('mnmissimwr of Iarenrs and Trademarks Li J
Claims (14)
1. A COMPOSITION OF MATTER COMPRISING AN INTIMATE ADMIXTURE OF A THERMOPLASTIC PHYSIOLOGICALLY-INERT HYDROXYPROPYL CELLULOSE OR HYDROXYPROPYLMETHYL CELLULOSE POLYMER SLUBLE IN VAGINAL FLUIDS SHAPED AS AN INTRA-VAGINAL MEDICAMENT APPLICATOR AND UP TO 30 WEIGHT PERCENT OF A VAGINAL MEDICAMENT APPLICAINTIMATE MIXTURE HAVING BEEN MELT SPUN BY BEING MELTED, SPUN, CAST MOLDED OR EXTRUDED IN THE MOLTEN STATE INTO A FIBROUS MASS OF FINE FIBERS, STRANDS, PELLETS, BALLS OR WADS THE ENTIRE MASS TOTALLY DISSOLVING IN SAID VAGINAL WITHIN ABOUT 24 HOURS.
2. The composition of claim 1 wherein the polymer is hydroxypropyl cellulose.
3. The composition of claim 2 in which the medicament is a spermicide, ovacide, antimicrobial, prostaglandin, steroidal or non-steroidal antifertility agent.
4. The composition of claim 3 wherein the medicament is a spermicide.
5. The composition of claim 4 wherein the spermicide is present in an amount ranging from 5 to 25 percent by weight based on the weight of the entire composition.
6. The composition of claim 5 wherein the polymer is a hydroxypropyl cellulose.
7. The composition of claim 6 wherein the spermicide is nonylphenoxypoly(ethoxy)n ethanol wherein n is 9.
8. The composition of claim 6 wherein the spermicide is p-diisobutylphenoxypolyethoxy ethanol.
9. The composition of claim 5 wherein the polymer is a hydroxypropylmethyl cellulose.
10. The composition of claim 9 wherein the spermicide is nonylphenoxypoly(ethoxy)n ethanol or p-diisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.
11. The composition of claim 6 wherein the composition is in the form of a fibrous mass having a fiber diameter of from 0.0004 to 0.0015 inches, and a bulk density of from 0.11 to 0.15 gms. per cubic cm.
12. The composition of claim 11 wherein the spermicide is nonylphenoxypoly(ethoxy)n ethanol or p-diisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.
13. The method for delivering a vaginal medicament to a site within the vagina from a solid medicament delivery system which comprises introducing within the vagina an effective amount of the composition of claim 1.
14. The method of claim 13 wherein the composition employed is from 5 to 25 percent by weight of a spermicide admixed in a hydroxypropyl cellulose.
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US316175A US3875300A (en) | 1972-12-18 | 1972-12-18 | Composition for sustained release of a medicament and method of using same |
GB5704473A GB1446626A (en) | 1972-12-18 | 1973-12-10 | Composition for sustained release of a medicament and method of using same |
FR7344027A FR2210415B1 (en) | 1972-12-18 | 1973-12-10 | |
BE138771A BE808519A (en) | 1972-12-18 | 1973-12-11 | MEDICINAL PRODUCT FOR SUSTAINED RELEASE OF AN ACTIVE INGREDIENT AND METHOD OF USE OF THIS MEDICINAL PRODUCT |
ZA00739502A ZA739502B (en) | 1972-12-18 | 1973-12-14 | Compositions for sustained release of a medicament and method of using same |
IT54360/73A IT1047937B (en) | 1972-12-18 | 1973-12-17 | COMPOSITION FOR THE GRADUAL TRANSFER OF A MEDICATION |
IL43839A IL43839A0 (en) | 1972-12-18 | 1973-12-17 | Compositions for sustained release of a medicament |
AU63720/73A AU6372073A (en) | 1972-12-18 | 1973-12-17 | Sustained release of a medicament |
JP48139715A JPS49133519A (en) | 1972-12-18 | 1973-12-17 | |
BR9861/73A BR7309861D0 (en) | 1972-12-18 | 1973-12-17 | VEHICLE INERT TO PROVIDE A PROLONGED DISCHARGE OF ACTIVE SUBSTANCE |
AT1060573A AT332532B (en) | 1972-12-18 | 1973-12-18 | PROCESS FOR MANUFACTURING A MEDICINAL PRODUCT TO BE USED INTRAVAGINALLY |
DE2362991A DE2362991A1 (en) | 1972-12-18 | 1973-12-18 | MEDICINAL PREPARATIONS FOR DIRECT INTRODUCTION INTO KOERPERHOEHLEN |
NL7317324A NL7317324A (en) | 1972-12-18 | 1973-12-18 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US316175A US3875300A (en) | 1972-12-18 | 1972-12-18 | Composition for sustained release of a medicament and method of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
US3875300A true US3875300A (en) | 1975-04-01 |
Family
ID=23227840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US316175A Expired - Lifetime US3875300A (en) | 1972-12-18 | 1972-12-18 | Composition for sustained release of a medicament and method of using same |
Country Status (13)
Country | Link |
---|---|
US (1) | US3875300A (en) |
JP (1) | JPS49133519A (en) |
AT (1) | AT332532B (en) |
AU (1) | AU6372073A (en) |
BE (1) | BE808519A (en) |
BR (1) | BR7309861D0 (en) |
DE (1) | DE2362991A1 (en) |
FR (1) | FR2210415B1 (en) |
GB (1) | GB1446626A (en) |
IL (1) | IL43839A0 (en) |
IT (1) | IT1047937B (en) |
NL (1) | NL7317324A (en) |
ZA (1) | ZA739502B (en) |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS50105814A (en) * | 1973-12-17 | 1975-08-20 | ||
US3946734A (en) * | 1975-02-19 | 1976-03-30 | The United States Of America As Represented By The Secretary Of State | Apparatus for controlling the release of a drug |
US3982537A (en) * | 1974-12-30 | 1976-09-28 | Louis Bucalo | Dynamic implants and method for implanting the same |
US4045558A (en) * | 1975-10-08 | 1977-08-30 | Merck & Co., Inc. | Pilocarpine salts |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4136145A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
US4179497A (en) * | 1973-12-17 | 1979-12-18 | Merck & Co., Inc. | Solid state ophthalmic medication |
DE2940146A1 (en) * | 1978-10-17 | 1980-04-30 | Stolle Res & Dev | MICROPARTICLES FOR THE TREATMENT OF THE INTERNAL FEMALE GENDER ORGANS AND THEIR USE |
EP0016051A4 (en) * | 1978-06-09 | 1980-07-17 | Donald Entpr Inc | Contraceptive-antivenereal disease tampon. |
US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
US4265875A (en) * | 1976-07-23 | 1981-05-05 | Inveresk Research International | Controlled release suppositories |
US4287175A (en) * | 1978-06-22 | 1981-09-01 | Merck & Co., Inc. | Contact lens wetting agents |
US4309997A (en) * | 1978-06-09 | 1982-01-12 | Donald Jack W | Contraceptive and/or antivenereal disease tampon |
US4343787A (en) * | 1975-07-29 | 1982-08-10 | Merck & Co., Inc. | Shaped ophthalmic inserts for treating dry eye syndrome |
US4344968A (en) * | 1978-12-09 | 1982-08-17 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical vehicle |
US4585651A (en) * | 1978-10-17 | 1986-04-29 | Stolle Research & Development Corporation | Active/passive immunization of the internal female reproductive organs |
US4673565A (en) * | 1985-05-03 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Pharmaceutical compositions containing hollow fine tubular drug delivery systems |
EP0250125A2 (en) * | 1986-06-03 | 1987-12-23 | Smith & Nephew plc | Drug delivery device, its preparation and use |
US4732763A (en) * | 1978-10-17 | 1988-03-22 | Stolle Research And Development Corporation | Active/passive immunization of the internal female reproductive organs |
WO1988008296A1 (en) * | 1987-04-20 | 1988-11-03 | Fuisz Richard C | A spun fibrous cosmetic and method of use |
WO1988008298A1 (en) * | 1987-04-20 | 1988-11-03 | Fuisz Richard C | Rapidly dissoluble medicinal dosage unit and method of manufacture |
US4841968A (en) * | 1986-09-26 | 1989-06-27 | Southern Research Institute | Antithrombotic/thrombolytic suture and methods of making and using the same |
WO1990011017A1 (en) * | 1989-03-20 | 1990-10-04 | Fuisz Pharmaceutical Ltd. | A moderated spun fibrous system and method of manuacture |
US4997856A (en) * | 1987-04-20 | 1991-03-05 | Fuisz Pharmaceutical Ltd. | Method of producing compacted dispersable systems |
US5236734A (en) * | 1987-04-20 | 1993-08-17 | Fuisz Technologies Ltd. | Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix |
US5238696A (en) * | 1987-04-20 | 1993-08-24 | Fuisz Technologies Ltd. | Method of preparing a frozen comestible |
US5268110A (en) * | 1991-05-17 | 1993-12-07 | Fuisz Technologies Ltd. | Oil removing method |
US5279849A (en) * | 1992-05-12 | 1994-01-18 | Fuisz Technologies Ltd. | Dispersible polydextrose, compositions containing same and method for the preparation thereof |
US5286513A (en) * | 1987-04-20 | 1994-02-15 | Fuisz Technologies Ltd. | Proteinaceous food product containing a melt spun oleaginous matrix |
US5348758A (en) * | 1992-10-20 | 1994-09-20 | Fuisz Technologies Ltd. | Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material |
US5380529A (en) * | 1990-07-10 | 1995-01-10 | Laboratoire Lucchini S.A. | Pharmaceutical, vaginal applicable preparation and a process for its preparation |
US5380473A (en) * | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
US5387431A (en) * | 1991-10-25 | 1995-02-07 | Fuisz Technologies Ltd. | Saccharide-based matrix |
US5407676A (en) * | 1990-12-14 | 1995-04-18 | Fuisz Technologies Ltd. | Hydrophilic form of perfluoro compounds and a method of manufacture |
US5427804A (en) * | 1992-03-05 | 1995-06-27 | Fuisz Technologies Ltd. | Low-fat edible proteins with maltodextrins and low-saturate oils |
US5445769A (en) * | 1994-06-27 | 1995-08-29 | Fuisz Technologies Ltd. | Spinner head for flash flow processing |
US5456932A (en) * | 1987-04-20 | 1995-10-10 | Fuisz Technologies Ltd. | Method of converting a feedstock to a shearform product and product thereof |
US5472731A (en) * | 1987-04-20 | 1995-12-05 | Fuisz Technologies Ltd. | Protein based food product |
US5501858A (en) * | 1992-05-12 | 1996-03-26 | Fuisz Technologies Ltd. | Rapidly dispersable compositions containing polydextrose |
US5512289A (en) * | 1993-07-28 | 1996-04-30 | Johnson & Johnson Consumer Products, Inc. | Spermicidal anti-viral lubricant composition and method of using same |
US5516537A (en) * | 1987-04-20 | 1996-05-14 | Fuisz Technologies Ltd. | Frozen comestibles |
US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
US5518551A (en) * | 1993-09-10 | 1996-05-21 | Fuisz Technologies Ltd. | Spheroidal crystal sugar and method of making |
US5520859A (en) * | 1993-10-07 | 1996-05-28 | Fuisz Technologies Ltd. | Method for flash flow processing having feed rate control |
US5545615A (en) * | 1987-09-18 | 1996-08-13 | Zymogenetics, Inc. | A method of inhibiting fertilization by alpha-1-antitrypsin or antithrombin III |
US5549917A (en) * | 1994-07-01 | 1996-08-27 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
US5556652A (en) * | 1994-08-05 | 1996-09-17 | Fuisz Technologies Ltd. | Comestibles containing stabilized highly odorous flavor component delivery systems |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US5576042A (en) * | 1991-10-25 | 1996-11-19 | Fuisz Technologies Ltd. | High intensity particulate polysaccharide based liquids |
US5587198A (en) * | 1995-05-31 | 1996-12-24 | Fuisz Technologies Ltd. | Positive hydration method of preparing confectionery and product therefrom |
US5593502A (en) * | 1993-10-07 | 1997-01-14 | Fuisz Technologies Ltd. | Method of making crystalline sugar and products resulting therefrom |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5624684A (en) * | 1991-05-17 | 1997-04-29 | Fuisz Technologies Ltd. | Enzyme systems |
US5651987A (en) * | 1991-12-17 | 1997-07-29 | Fuisz Technologies Ltd. | Ulcer prevention and treatment composition |
US5654003A (en) * | 1992-03-05 | 1997-08-05 | Fuisz Technologies Ltd. | Process and apparatus for making tablets and tablets made therefrom |
US5728397A (en) * | 1992-05-12 | 1998-03-17 | Fuisz Technologies Ltd. | Polydextrose product and process |
US5843922A (en) * | 1994-07-29 | 1998-12-01 | Fuisz Technologies Ltd. | Preparation of oligosaccharides and products therefrom |
US5851553A (en) * | 1993-09-10 | 1998-12-22 | Fuisz Technologies, Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5895664A (en) * | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US6020002A (en) * | 1994-06-14 | 2000-02-01 | Fuisz Technologies Ltd. | Delivery of controlled-release system(s) |
US20040131664A1 (en) * | 2003-01-03 | 2004-07-08 | Mo Y. Joseph | Topical stabilized prostaglandin E compound dosage forms |
US20120058166A1 (en) * | 2010-07-02 | 2012-03-08 | Glenn Jr Robert Wayne | Filaments comprising a non-perfume active agent nonwoven webs and methods for making same |
US20130136784A1 (en) * | 2007-10-11 | 2013-05-30 | Robert J. Staab | Methods for delivery of medication using dissolvable devices |
CN114397391A (en) * | 2022-01-21 | 2022-04-26 | 苏州南医大创新中心 | Ricinoleic acid as molecular marker related to azoospermia in semen and detection method and application thereof |
US11434586B2 (en) | 2010-07-02 | 2022-09-06 | The Procter & Gamble Company | Filaments comprising an active agent nonwoven webs and methods for making same |
US11666514B2 (en) | 2018-09-21 | 2023-06-06 | The Procter & Gamble Company | Fibrous structures containing polymer matrix particles with perfume ingredients |
US11679066B2 (en) | 2019-06-28 | 2023-06-20 | The Procter & Gamble Company | Dissolvable solid fibrous articles containing anionic surfactants |
US11925698B2 (en) | 2020-07-31 | 2024-03-12 | The Procter & Gamble Company | Water-soluble fibrous pouch containing prills for hair care |
US11944696B2 (en) | 2010-07-02 | 2024-04-02 | The Procter & Gamble Company | Detergent product and method for making same |
US11944693B2 (en) | 2010-07-02 | 2024-04-02 | The Procter & Gamble Company | Method for delivering an active agent |
US11951194B2 (en) | 2017-01-27 | 2024-04-09 | The Procter & Gamble Company | Compositions in the form of dissolvable solid structures comprising effervescent agglomerated particles |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE431821B (en) | 1979-01-29 | 1984-03-05 | Perstorp Ab | STORAGE STABLE, PROSTAGLANDIN-CONTAINING MEDICAL PREPARATION |
JPS5634619A (en) * | 1979-08-31 | 1981-04-06 | Ono Pharmaceut Co Ltd | Production of prostaglandin vaginal suppository |
JPS5832816A (en) * | 1981-08-20 | 1983-02-25 | Shin Etsu Chem Co Ltd | Contraceptive film pharmaceutical |
JPS58206512A (en) * | 1982-05-27 | 1983-12-01 | ウイジヤヤ・チヤンドラ | Female external contraception membrane |
ES2017282A6 (en) * | 1989-07-28 | 1991-01-16 | Aguilera Franco Maria | Dressing for transcutaneous application of active substances for therapeutic or cosmetic purposes. |
DE102020131179A1 (en) | 2020-11-25 | 2022-05-25 | Universität Rostock | Resorbable three-dimensional hollow-fiber structure for use in tamponades and/or wound dressings and method for producing an absorbable three-dimensional hollow-fiber structure for use in tamponades and/or wound dressings |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3067743A (en) * | 1958-11-12 | 1962-12-11 | Alginate Ind Ltd | Alginic compounds |
US3108043A (en) * | 1960-05-09 | 1963-10-22 | Ortho Pharma Corp | Spermicidal sheet-like material |
-
1972
- 1972-12-18 US US316175A patent/US3875300A/en not_active Expired - Lifetime
-
1973
- 1973-12-10 FR FR7344027A patent/FR2210415B1/fr not_active Expired
- 1973-12-10 GB GB5704473A patent/GB1446626A/en not_active Expired
- 1973-12-11 BE BE138771A patent/BE808519A/en unknown
- 1973-12-14 ZA ZA00739502A patent/ZA739502B/en unknown
- 1973-12-17 AU AU63720/73A patent/AU6372073A/en not_active Expired
- 1973-12-17 BR BR9861/73A patent/BR7309861D0/en unknown
- 1973-12-17 JP JP48139715A patent/JPS49133519A/ja active Pending
- 1973-12-17 IT IT54360/73A patent/IT1047937B/en active
- 1973-12-17 IL IL43839A patent/IL43839A0/en unknown
- 1973-12-18 AT AT1060573A patent/AT332532B/en not_active IP Right Cessation
- 1973-12-18 NL NL7317324A patent/NL7317324A/xx unknown
- 1973-12-18 DE DE2362991A patent/DE2362991A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3067743A (en) * | 1958-11-12 | 1962-12-11 | Alginate Ind Ltd | Alginic compounds |
US3108043A (en) * | 1960-05-09 | 1963-10-22 | Ortho Pharma Corp | Spermicidal sheet-like material |
Cited By (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5636173B2 (en) * | 1973-12-17 | 1981-08-22 | ||
US4179497A (en) * | 1973-12-17 | 1979-12-18 | Merck & Co., Inc. | Solid state ophthalmic medication |
JPS50105814A (en) * | 1973-12-17 | 1975-08-20 | ||
US4136145A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
US3982537A (en) * | 1974-12-30 | 1976-09-28 | Louis Bucalo | Dynamic implants and method for implanting the same |
US3946734A (en) * | 1975-02-19 | 1976-03-30 | The United States Of America As Represented By The Secretary Of State | Apparatus for controlling the release of a drug |
US4343787A (en) * | 1975-07-29 | 1982-08-10 | Merck & Co., Inc. | Shaped ophthalmic inserts for treating dry eye syndrome |
US4045558A (en) * | 1975-10-08 | 1977-08-30 | Merck & Co., Inc. | Pilocarpine salts |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4265875A (en) * | 1976-07-23 | 1981-05-05 | Inveresk Research International | Controlled release suppositories |
US4292300A (en) * | 1976-07-23 | 1981-09-29 | Inveresk Research International | Controlled release suppositories |
US4309997A (en) * | 1978-06-09 | 1982-01-12 | Donald Jack W | Contraceptive and/or antivenereal disease tampon |
EP0016051A4 (en) * | 1978-06-09 | 1980-07-17 | Donald Entpr Inc | Contraceptive-antivenereal disease tampon. |
EP0016051A1 (en) * | 1978-06-09 | 1980-10-01 | Donald, Enterprises, Inc. | Contraceptive-antivenereal disease tampon |
US4287175A (en) * | 1978-06-22 | 1981-09-01 | Merck & Co., Inc. | Contact lens wetting agents |
US4732763A (en) * | 1978-10-17 | 1988-03-22 | Stolle Research And Development Corporation | Active/passive immunization of the internal female reproductive organs |
US4585651A (en) * | 1978-10-17 | 1986-04-29 | Stolle Research & Development Corporation | Active/passive immunization of the internal female reproductive organs |
DE2940146A1 (en) * | 1978-10-17 | 1980-04-30 | Stolle Res & Dev | MICROPARTICLES FOR THE TREATMENT OF THE INTERNAL FEMALE GENDER ORGANS AND THEIR USE |
US4344968A (en) * | 1978-12-09 | 1982-08-17 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical vehicle |
US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
US4673565A (en) * | 1985-05-03 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Pharmaceutical compositions containing hollow fine tubular drug delivery systems |
US4784857A (en) * | 1986-06-03 | 1988-11-15 | Smith And Nephew Associated Companies Plc | Drug delivery device, its preparation and use |
EP0250125A2 (en) * | 1986-06-03 | 1987-12-23 | Smith & Nephew plc | Drug delivery device, its preparation and use |
EP0250125A3 (en) * | 1986-06-03 | 1989-04-19 | Smith And Nephew Associated Companies P.L.C. | Drug delivery device, its preparation and use |
US4841968A (en) * | 1986-09-26 | 1989-06-27 | Southern Research Institute | Antithrombotic/thrombolytic suture and methods of making and using the same |
US5456932A (en) * | 1987-04-20 | 1995-10-10 | Fuisz Technologies Ltd. | Method of converting a feedstock to a shearform product and product thereof |
US4855326A (en) * | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
US5516537A (en) * | 1987-04-20 | 1996-05-14 | Fuisz Technologies Ltd. | Frozen comestibles |
US4873085A (en) * | 1987-04-20 | 1989-10-10 | Fuisz Pharmaceutical Ltd. | Spun fibrous cosmetic and method of use |
EP0357665A1 (en) * | 1987-04-20 | 1990-03-14 | Fuisz Pharmaceutical Ltd | Rapidly dissoluble medicinal dosage unit and method of manufacture. |
US5503862A (en) * | 1987-04-20 | 1996-04-02 | Fuisz Technologies Ltd. | Method of subjecting a protein-containing material to flash flow processing and product thereof |
US4997856A (en) * | 1987-04-20 | 1991-03-05 | Fuisz Pharmaceutical Ltd. | Method of producing compacted dispersable systems |
US5236734A (en) * | 1987-04-20 | 1993-08-17 | Fuisz Technologies Ltd. | Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix |
US5238696A (en) * | 1987-04-20 | 1993-08-24 | Fuisz Technologies Ltd. | Method of preparing a frozen comestible |
WO1988008296A1 (en) * | 1987-04-20 | 1988-11-03 | Fuisz Richard C | A spun fibrous cosmetic and method of use |
US5490993A (en) * | 1987-04-20 | 1996-02-13 | Fuisz Technologies Ltd. | Method of preparing a proteinaceous food product containing a melt spun matrix and product thereof |
US5286513A (en) * | 1987-04-20 | 1994-02-15 | Fuisz Technologies Ltd. | Proteinaceous food product containing a melt spun oleaginous matrix |
US5472731A (en) * | 1987-04-20 | 1995-12-05 | Fuisz Technologies Ltd. | Protein based food product |
US5374447A (en) * | 1987-04-20 | 1994-12-20 | Fuisz Technologies Ltd. | Method of preparing a reduced-fat meat product |
WO1988008298A1 (en) * | 1987-04-20 | 1988-11-03 | Fuisz Richard C | Rapidly dissoluble medicinal dosage unit and method of manufacture |
US5545615A (en) * | 1987-09-18 | 1996-08-13 | Zymogenetics, Inc. | A method of inhibiting fertilization by alpha-1-antitrypsin or antithrombin III |
WO1990011017A1 (en) * | 1989-03-20 | 1990-10-04 | Fuisz Pharmaceutical Ltd. | A moderated spun fibrous system and method of manuacture |
US5380529A (en) * | 1990-07-10 | 1995-01-10 | Laboratoire Lucchini S.A. | Pharmaceutical, vaginal applicable preparation and a process for its preparation |
US5407676A (en) * | 1990-12-14 | 1995-04-18 | Fuisz Technologies Ltd. | Hydrophilic form of perfluoro compounds and a method of manufacture |
US6129926A (en) * | 1991-05-17 | 2000-10-10 | Fuisz Technologies Ltd. | Flash flow processing of thermoplastic polymers and products made therefrom |
US5624684A (en) * | 1991-05-17 | 1997-04-29 | Fuisz Technologies Ltd. | Enzyme systems |
US5268110A (en) * | 1991-05-17 | 1993-12-07 | Fuisz Technologies Ltd. | Oil removing method |
US5709876A (en) * | 1991-10-25 | 1998-01-20 | Fuisz Technologies Ltd. | Saccharide-based matrix |
US5429836A (en) * | 1991-10-25 | 1995-07-04 | Fuisz Technologies Ltd. | Saccharide-based matrix |
US5576042A (en) * | 1991-10-25 | 1996-11-19 | Fuisz Technologies Ltd. | High intensity particulate polysaccharide based liquids |
US5597608A (en) * | 1991-10-25 | 1997-01-28 | Fuisz Technologies Ltd. | Saccharide-based matrix incorporating maltodextrin and process for making |
US5387431A (en) * | 1991-10-25 | 1995-02-07 | Fuisz Technologies Ltd. | Saccharide-based matrix |
US5651987A (en) * | 1991-12-17 | 1997-07-29 | Fuisz Technologies Ltd. | Ulcer prevention and treatment composition |
US5427804A (en) * | 1992-03-05 | 1995-06-27 | Fuisz Technologies Ltd. | Low-fat edible proteins with maltodextrins and low-saturate oils |
US5654003A (en) * | 1992-03-05 | 1997-08-05 | Fuisz Technologies Ltd. | Process and apparatus for making tablets and tablets made therefrom |
US5501858A (en) * | 1992-05-12 | 1996-03-26 | Fuisz Technologies Ltd. | Rapidly dispersable compositions containing polydextrose |
US5279849A (en) * | 1992-05-12 | 1994-01-18 | Fuisz Technologies Ltd. | Dispersible polydextrose, compositions containing same and method for the preparation thereof |
US5728397A (en) * | 1992-05-12 | 1998-03-17 | Fuisz Technologies Ltd. | Polydextrose product and process |
US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
US5348758A (en) * | 1992-10-20 | 1994-09-20 | Fuisz Technologies Ltd. | Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material |
US5380473A (en) * | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
US5512289A (en) * | 1993-07-28 | 1996-04-30 | Johnson & Johnson Consumer Products, Inc. | Spermicidal anti-viral lubricant composition and method of using same |
US5827563A (en) * | 1993-09-10 | 1998-10-27 | Fuisz Technologies Ltd. | Spheroidal crystal sugar |
US5895664A (en) * | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5601076A (en) * | 1993-09-10 | 1997-02-11 | Fuisz Technologies Ltd. | Spheroidal crystal sugar and method of making |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5871781A (en) * | 1993-09-10 | 1999-02-16 | Fuisz Technologies Ltd. | Apparatus for making rapidly-dissolving dosage units |
US5866163A (en) * | 1993-09-10 | 1999-02-02 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5851553A (en) * | 1993-09-10 | 1998-12-22 | Fuisz Technologies, Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5518551A (en) * | 1993-09-10 | 1996-05-21 | Fuisz Technologies Ltd. | Spheroidal crystal sugar and method of making |
US5520859A (en) * | 1993-10-07 | 1996-05-28 | Fuisz Technologies Ltd. | Method for flash flow processing having feed rate control |
US5597416A (en) * | 1993-10-07 | 1997-01-28 | Fuisz Technologies Ltd. | Method of making crystalline sugar and products resulting therefrom |
US5593502A (en) * | 1993-10-07 | 1997-01-14 | Fuisz Technologies Ltd. | Method of making crystalline sugar and products resulting therefrom |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US6020002A (en) * | 1994-06-14 | 2000-02-01 | Fuisz Technologies Ltd. | Delivery of controlled-release system(s) |
US5733577A (en) * | 1994-06-14 | 1998-03-31 | Fuisz Technologies Ltd. | Delivery of controlled-release system (s) |
US5853762A (en) * | 1994-06-14 | 1998-12-29 | Fuisz Technologies Ltd | Delivery of controlled-release system(s) |
US5851552A (en) * | 1994-06-14 | 1998-12-22 | Fuisz Technologies, Ltd. | Delivery of controlled-release system(s) |
US5445769A (en) * | 1994-06-27 | 1995-08-29 | Fuisz Technologies Ltd. | Spinner head for flash flow processing |
US5824342A (en) * | 1994-07-01 | 1998-10-20 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
US5582855A (en) * | 1994-07-01 | 1996-12-10 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
US5549917A (en) * | 1994-07-01 | 1996-08-27 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
US5843922A (en) * | 1994-07-29 | 1998-12-01 | Fuisz Technologies Ltd. | Preparation of oligosaccharides and products therefrom |
US5556652A (en) * | 1994-08-05 | 1996-09-17 | Fuisz Technologies Ltd. | Comestibles containing stabilized highly odorous flavor component delivery systems |
US5633027A (en) * | 1994-08-05 | 1997-05-27 | Fuisz Technologies Ltd. | Confectioneries containing stabilized highly odorous flavor component delivery systems |
US5744180A (en) * | 1994-08-05 | 1998-04-28 | Fuisz Technologies Ltd. | Comestibles containing stabilized highly odorous flavor component delivery systems |
US5804247A (en) * | 1995-05-31 | 1998-09-08 | Fuisz Technologies Ltd. | Positive hydration method of preparing confectionary and product therefrom |
US5587198A (en) * | 1995-05-31 | 1996-12-24 | Fuisz Technologies Ltd. | Positive hydration method of preparing confectionery and product therefrom |
US20040131664A1 (en) * | 2003-01-03 | 2004-07-08 | Mo Y. Joseph | Topical stabilized prostaglandin E compound dosage forms |
US6841574B2 (en) * | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
US20130136784A1 (en) * | 2007-10-11 | 2013-05-30 | Robert J. Staab | Methods for delivery of medication using dissolvable devices |
US20120058166A1 (en) * | 2010-07-02 | 2012-03-08 | Glenn Jr Robert Wayne | Filaments comprising a non-perfume active agent nonwoven webs and methods for making same |
US11434586B2 (en) | 2010-07-02 | 2022-09-06 | The Procter & Gamble Company | Filaments comprising an active agent nonwoven webs and methods for making same |
US11944696B2 (en) | 2010-07-02 | 2024-04-02 | The Procter & Gamble Company | Detergent product and method for making same |
US11944693B2 (en) | 2010-07-02 | 2024-04-02 | The Procter & Gamble Company | Method for delivering an active agent |
US11951194B2 (en) | 2017-01-27 | 2024-04-09 | The Procter & Gamble Company | Compositions in the form of dissolvable solid structures comprising effervescent agglomerated particles |
US11666514B2 (en) | 2018-09-21 | 2023-06-06 | The Procter & Gamble Company | Fibrous structures containing polymer matrix particles with perfume ingredients |
US11679066B2 (en) | 2019-06-28 | 2023-06-20 | The Procter & Gamble Company | Dissolvable solid fibrous articles containing anionic surfactants |
US11925698B2 (en) | 2020-07-31 | 2024-03-12 | The Procter & Gamble Company | Water-soluble fibrous pouch containing prills for hair care |
CN114397391A (en) * | 2022-01-21 | 2022-04-26 | 苏州南医大创新中心 | Ricinoleic acid as molecular marker related to azoospermia in semen and detection method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
ZA739502B (en) | 1975-07-30 |
AT332532B (en) | 1976-10-11 |
IL43839A0 (en) | 1974-03-14 |
NL7317324A (en) | 1974-06-20 |
FR2210415A1 (en) | 1974-07-12 |
AU6372073A (en) | 1975-06-19 |
FR2210415B1 (en) | 1977-04-15 |
JPS49133519A (en) | 1974-12-21 |
ATA1060573A (en) | 1976-01-15 |
GB1446626A (en) | 1976-08-18 |
DE2362991A1 (en) | 1974-06-20 |
BR7309861D0 (en) | 1974-09-24 |
IT1047937B (en) | 1980-10-20 |
BE808519A (en) | 1974-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3875300A (en) | Composition for sustained release of a medicament and method of using same | |
US4317447A (en) | Drug delivery system | |
US4069307A (en) | Drug-delivery device comprising certain polymeric materials for controlled release of drug | |
US4016251A (en) | Vaginal drug dispensing device | |
US4052505A (en) | Ocular therapeutic system manufactured from copolymer | |
US4144317A (en) | Device consisting of copolymer having acetoxy groups for delivering drugs | |
US4160020A (en) | Therapeutic device for osmotically dosing at controlled rate | |
US3921636A (en) | Novel drug delivery device | |
US3888975A (en) | Erodible intrauterine device | |
US3918452A (en) | Tampons impregnated with contraceptive compositions | |
US3929132A (en) | Osmotic dispenser | |
US4629449A (en) | Vaginal dispenser for dispensing beneficial hormone | |
US3863633A (en) | Composition containing a substance showing a topical effect on the eye, and a method of preparing the same | |
US5004601A (en) | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith | |
US4402695A (en) | Device for delivering agent in vagina | |
US5139790A (en) | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith | |
US3916899A (en) | Osmotic dispensing device with maximum and minimum sizes for the passageway | |
US3896819A (en) | IUD having a replenishing drug reservoir | |
US4011312A (en) | Prolonged release drug form for the treatment of bovine mastitis | |
US5244668A (en) | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith | |
US5556633A (en) | Drug delivery ophthalmic insert and method for preparing same | |
US4308867A (en) | Two-member medicated device for rate-controlled administration of lipophilic pharmaceuticals | |
US3948262A (en) | Novel drug delivery device | |
US4542020A (en) | Long-lasting adhesive antifungal suppositories | |
US3880991A (en) | Polymeric article for dispensing drugs |